Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
4 articles
Newest firstBackground Cannabinoids may be useful to treat pain, epilepsy and spasticity, although they may bear an increased risk of cardiovascular events. This study aims to evaluate the cardiovascular safety of nabiximols, a cannabis-based drug, in patients with spasticity following stroke, thus presenting an increased cardiovascular risk. Methods This is an ancillary study stemming from the SativexStroke trial: a randomiz…
Open article record in new tab ↗Background and Aims: Illicit drug use is an ongoing health and social issue in Canada. This study aimed to investigate the prevalence of illicit drug use and its implications for suicidal behaviors, and household food insecurity in Canada. Design: Cross-sectional population survey. Setting: Canada, using the 2015-2016 Canadian Community Health Survey, a nationally representative sample selected by stratified multi…
Open article record in new tab ↗BackgroundTo estimate the burden of myocarditis (MC) and cardiomyopathy for 195 countries and territories from 1990 to 2017. MethodsWe collected detailed information on MC and cardiomyopathy between 1990 and 2017 from the Global Burden of Disease study (GBD) 2017. Cardiomyopathy was divided into two types in GBD 2017, including alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC). All estimates were present…
Open article record in new tab ↗Erythrodermic psoriasis (EP) is a dermatological emergency and its treatment with secukinumab is still controversial. Furthermore, no data exist regarding the prognostic value of drug abuse in such a condition. We performed a multi-center, international, retrospective study, enrolling a sample of EP patients (body surface area > 90%) who were treated with secukinumab (300 mg) during the study period from December…
Open article record in new tab ↗